Introduction 52

Legionella pneumophila
1 is the most common intracellular bacteria responsible for 53 severe pneumonia.
2 Its incidence was estimated to 1.2 per 100 000 inhabitants in 2010. 3 Risk 54 factors include a male gender, a smoking habit, a history of chronic lung disease or 55 immunosuppression, as well as travel and stay in large buildings, including hotels and 56 hospitals.
1, 4-6 Prognosis factors include appropriateness and timing of initial antimicrobial 57 therapy. 7, 8 58 Legionellosis mostly presents as a mild-to-moderate disease. Severe systemic cases 59 have been reported. [9] [10] [11] The overall mortality has been estimated to 12%, 12 and to 15-20% in 60 hospitalized patients. Mortality seems higher in nosocomial cases (15-40% versus 10-20% in 61 community-acquired cases). 13 As a result, when initiating an empiric antimicrobial therapy for 62 a severe pneumonia, current guidelines recommend to perform urinary diagnostic tests and to 63 initiate a treatment for both Streptococcus pneumoniae, the most frequent bacteria involved in 64 severe pneumonia, and Legionella spp. 14, 15 65 Although erythromycin was the recommended treatment since the first reported outbreak of 66 legionellosis, other agents have been developed. Recommended antimicrobials include 67 quinolones and new macrolides. These recommendations are based on scarce data from in 68 vitro and animal studies. Few data are available in humans and none allowed for a definitive 69 conclusion. Consequently, the debate on which antimicrobial should be used in patients with 70 legionellosis and/or to target Legionella spp. in patients with pneumonia is still ongoing. 71
No randomized clinical trial (RCT) has been performed for efficacy comparison. We 72 performed a systematic review and meta-analysis to compare the clinical efficacy of a 73 monotherapy of quinolone or macrolide in the treatment of legionellosis. 74
Material and methods 75
Data sources
Using Cochrane methodology, 16 we conducted a systematic search of the literature. PubMed, 77
Embase and the Cochrane Central Register of Controlled Trials databases were searched from 78 01/01/1985 to 01/31/2013. 79 Search terms included: quinolone, fluoroquinolone, ofloxacin, ciprofloxacin, pefloxacin, 80 trovafloxacin, levofloxacin, moxifloxacin, gatifloxacin, clinafloxacin, enoxacin, 81 grepafloxacin, parfloxacin, norfloxacin, cinoxacin, macrolide, azithromycin, clarithromycin, 82 erythromycin, spiramycin, roxithromycin. We also included related MeSH terms and Emtree 83 entries. Two queries were performed. The first one ('legionellosis query', Table S1 as an 84 example) aimed to identify studies providing data in legionellosis. In this query, 'legionella', 85
'legionnaire' and 'legionellosis' terms were added to those aforementioned. In the second 86 query, all RCTs performed to compare antimicrobial efficacy in community-acquired 87 pneumonia were searched ('RCTs in pneumonia query', Table S2 as an example). In this 88 second query, the term 'pneumonia' was added. 
Study selection 95
Title and abstract were independently assessed for eligibility by two authors (CB and RL). 96
Full text of eligible studies and congress abstracts were independently examined for final 97 inclusion. The opinion of a third investigator (YY) was asked in case of disagreement. 98
Original studies providing data for comparison of the efficacy of quinolones and macrolides 99 in legionellosis were included. In vitro and animal studies were excluded. Legionellosisdiagnosis had to be proven using urinary antigen, serology, sputum or tracheal aspirate 101 analyzed by culture or PCR. 102
Data extraction 103
Data were extracted using a standardized form: patient population, number of participating 104 centres, number of patients included, antimicrobial agents and doses used, clinical outcomes, 105 severity assessed by the Fine score and adverse effects. 106
Outcomes 107
Primary outcome was mortality in each treatment group. Secondary outcomes included 108 clinical cure, time to apyrexia, length of hospital stay, occurrence of complications defined by 109 studies' authors, need for mechanical ventilation and occurrence of adverse effects. 110
Risk of bias assessment 111
Risk of bias was assessed using the Newcastle-Ottawa scale.
17 This 8-item scale is suggested 112 by the Cochrane collaboration for risk of bias assessment of nonrandomized studies. 16 
113
However we also used this scale for included RCTs. 114
Statistical analysis 115
The analysis focused on patients treated by antimicrobial monotherapy. β-lactams were not 116 considered as effective anti-Legionella antimicrobials. We estimated pooled odds ratios and 117 their 95% confidence intervals (95%CIs) comparing between quinolones and macrolides the 118 probability of occurrence of qualitative outcomes. We estimated mean differences for time to 119 apyrexia and length of hospital stay. Estimates were determined using a Mantel-Haenszel 120 random effects model. 16 Statistical heterogeneity was assessed using the chi-square test for 121 heterogeneity and the I² statistic for measuring inconsistency. Analyses were performed using 122 Review Manager v5.2 (Cochrane Collaboration, Oxford, United Kingdom). 123
Results
124
Identification of eligible studies
Databases queries identified 1005 articles and/or congress abstracts. Most were not 126 eligible, and 96 full-text articles were retrieved and read for inclusion (Figure 1 ). Of those, 12 127 were finally included. All were original articles.
7, 18-28 Nine were observational cohort 128 studies, 7, 18, 20, [23] [24] [25] [26] [27] [28] of which six were retrospective. 18, 20, 23, [26] [27] [28] They were performed in Spain 129 (n=4), 7, [23] [24] [25] in France (n=2), 18, 20 and Japan (n=2). 26, 27 One was international. 28 The three 130 remaining studies were RCTs conducted in patients with pneumonia. 19, 21, 22 Two of them 131 were performed in the USA, 21, 22 the third was international. 19 Five of the 12 studies were 132 conducted in a single centre. 7, 20, 23, 24, 26 133
Risk of bias 134
Overall risk of bias is represented in Figure S1 . 
172
One study provided data for analysis of time to apyrexia. 23 The time to apyrexia was 173 shorter with quinolones than with macrolides, but the difference was not significant (mean 174 difference, -4.8 hours [95%CI, -22.1; 12.5], Figure 2C ).Three studies were available for the comparison of length of hospital-stay ( Figure  176 2D). 23, 27, 28 One of them showed a significant reduction of the length of hospital-stay with 177 quinolones versus macrolides (-2.8, 95%CI, -5.4; -0.2). 23 We found an overall significant 178 mean reduction of 3.0 days with quinolones versus macrolides (95%CI, -5.3; -0.7). Test for 179 heterogeneity was not significant (I²=0%, p=0.9). 180
Two studies were included in the analysis of complications ( Figure 2E) . 23, 25 These 181 studies defined complicated legionellosis either as the apparition of pleural effusion, 182 empyema, mechanical ventilation or septic shock; 25 or renal failure, pleural effusion or 183 admission to ICU. 23 The combined odds ratio of complications when treated with quinolones 184 versus macrolides, was 0.5 [95%CI, 0.1; 1.6]). 185
Adverse effects 186
In the only study providing data on adverse events, 23 the three main reported events 187 were gastrointestinal events (5 -7%), liver abnormalities (2 -3%) and phlebitis, which 188 occurred more frequently in patients receiving clarithromycin than in those under 189 levofloxacin therapy (p<0.01). 190
Discussion 191
This is the first systematic review and meta-analysis of the effectiveness of quinolones 192 versus macrolides in the treatment of legionellosis. We found that despite a small number of 193 studies addressing this issue in clinical settings -and a small number of patients in each study 194 -quinolones seem to have a higher effectiveness than macrolides. Quinolone therapy was 195 significantly associated with a shorter length of hospital-stay, and we observed a trend toward 196 a reduced mortality, a higher clinical cure, a lower time to apyrexia, and a lower rate of 197 complications in patients receiving a quinolone. 198
Our analysis is unique. Published reviews on this topic did not use a systematic 199 methodology for studies inclusion and results analysis. 29, 30 In the absence of RCTs, the type 200 of analysis we conducted is the most accurate way to compare quinolones and macrolides 201 effectiveness in patients with legionellosis and to improve management of this disease. 202
This question has been investigated in experimental models. In all but one of the 19 203 intracellular models reviewed by Pedro-Botet and Yu, quinolones had a higher activity on 204
Legionella pneumophila than macrolides. 29 Levofloxacin was the most effective quinolone 205 and azithromycin the most effective macrolide. In animal models of Legionella pneumophila 206 infection, treatment with quinolones resulted in an increased survival. 29 However, these 207 experimental results may not be generalisable to humans. 208
Despite a non-significant difference, results for all studied outcomes favoured 209 quinolones. The absence of significance in these comparisons may be related to a lack of 210 statistical power. However, none of the included studies attempted to control for confounding. 211
Patients treated with macrolides had higher severity of disease. This might favour quinolones. 212
Moreover, the macrolide agent used was mostly erythromycin, which is not the most effective 213 macrolide agent as observed in in vitro studies. 29 It was the only macrolide used in the study 214 performed by Dournon et al, 18 in which the number of deaths in the macrolide group 215 accounted for 40% of overall deaths observed in our review, and with a mortality rate of 50% 216 in this group. 217
This study has some other limitations. First, statistical methodology is limited by the 218 observational design of most included studies. RCTs were not designed for a proper analysis 219 in legionellosis. We used random effects modelling to limit inherent bias. Moreover, our 220 results are strengthened by the absence of heterogeneity. Second, a small number of studies 221 were included. Legionellosis is a rare disease. The systematic strategy used for inclusion 222 aimed to minimize misidentifications and to limit publication bias. However, reporting bias is 223 a recurrent problem in systematic reviews and unpublished work could not be retrieved by our 224 search strategy. Third, we were not able to perform subgroup analysis and/or to adjust ondisease severity or prognosis factors. Finally, we could not perform a face-to-face comparison 226 of individual quinolones and macrolides as individual data were not available. 227
In light of our results, should we prefer quinolones or macrolides when treating a 228 patient with a proven Legionella pneumonia? Our analysis does not provide a high level of 229 evidence for conclusion. When answering this thorny question, risks associated with the 230 administration of these antimicrobials should be considered. Quinolones are generally well-231 tolerated drugs; serious adverse events are rare. There is a rare risk of cardiac toxicity with 232 macrolides, but azithromycin is generally considered to be free of serious adverse effects. [31] [32] [33] 233 Both quinolones and macrolides have been associated with an increased risk of developing a 234
Clostridium difficile infection, with a higher risk for quinolones. 34 The emergence of bacterial 235 resistance in the digestive microbiota has been documented with quinolones, 35 but such 236 consideration should not restrain their use when treating a potentially fatal infection. 237
We believe that quinolones might be preferred for proven legionellosis, especially in 238 patients with severe legionellosis. Empirical antimicrobial therapy for patients with severe 239 pneumonia might benefit of a combination of a β-lactam and a quinolone, when a Legionella 240 infection is suspected. However, in patients with mild pneumonia from uncertain origin, the 241 potential negative impact of quinolones on the digestive microbiota should be balanced with 242 Total (95% CI) Heterogeneity: Tau² = 0.00; Chi² = 0.12, df = 2 (P = 0.94); I² = 0% Test for overall effect: Z = 2.57 (P = 0.01) Total (95% CI) Heterogeneity: Tau² = 0.00; Chi² = 0.12, df = 2 (P = 0.94); I² = 0% Test for overall effect: Z = 2.57 (P = 0.01) 
